Epidemiologists have long suspected that, in populations with racial or ethnic subgroups, spurious associations may arise between genetic markers and disease (1) . Incomplete mixing of subgroups, known as population stratification or admixture, can lead to bias if one more or subgroups carries both a higher prevalence of an allele and a higher risk of disease (2) . The magnitude and direction of the resulting bias are not well understood. Recently, a variety of alternative study designs have been proposed to avoid the problem of population stratification, including case-parent and case-sibling methods (2) .
In a recent issue of the Journal, Wacholder et al. (3) provided evidence that population stratification leads to minimal bias in epidemiologic studies of non-Hispanic U. S. Caucasians of European origin. The authors calculated a confounding risk ratio (CRR), the ratio of the crude and race-adjusted relative risks for the effect of genotype on disease. With the use of empiric data as well as data simulations, the authors found that the range of CRRs for European-Americans was 0.78-1.22. The majority of CRR values centered around the null value of 1.00, indicating no confounding by race.
I performed similar calculations using previously published data from the Carolina Breast Cancer Study, a population-based, case-control study of inasive breast cancer in North Carolina. The study was approved by the Institutional Review Board at the University of North Carolina School of Medicine, Chapel Hill, and written informed consent was obtained from all study participants. The study population is 41% African-American, 58% white, and 1% other groups. Data for glutathione S-transferase M1, T1, and P1 (4); N-acetyltransferase 1 and 2 (5); catechol-O-methyltransferase (6); and P57/KIP2 (7) genotypes were used. The previously reported odds ratios (ORs) for "at-risk" genotypes ranged from 0.7 to 1.4, and there was little evidence for interaction between genotype and environmental exposures. For each genetic locus, logistic regression (implemented in SAS; SAS Institute, Cary, NC) was used to calculate a confounding OR (COR), the OR adjusted for age divided by the OR adjusted for age and race (3). Self-reported race was coded as a dichotomous variable, African-American versus non-AfricanAmerican. Non-African-Americans included whites, as well as seven Native Americans, three Asian-Americans, and three women who listed their race as "multiracial." CORs were also calculated after stratifying on smoking and a variety of other environmental factors.
The range of CORs for genotype was 0.94-1.12 (Table 1) . CORs deviated farther from the null (1.0) as the difference in genotype frequencies between African-Americans and whites increased, but most values were close to 1.0. After stratifying on environmental factors (data not shown), the range of CORs was 0.84-1.34, but most values remained close to the null. These results are compatible with the predictions of Wacholder et al. (3) and extend their findings to African-Americans and to whites. The results suggest that, in studies of breast cancer, failure to adjust for race does not lead to appreciable bias when estimating ORs for the genetic markers shown here. However, this finding may not apply to other cancers or other genetic markers. Del ‫ס‬ in-frame deletion of 12 base pairs, resulting in the loss of four amino acids (proline-alanineproline-alanine) in P57; and Wt ‫ס‬ wild-type allele of P57.
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†Odds ratio for genotype adjusted for sampling fractions used to identify eligible subjects and age divided by the odds ratio for genotype adjusted for sampling fractions, age and race. ‡*10 indicates one or more copies of the NAT1*10 allele.
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RESPONSE
Dr. Millikan's letter raises the question of how to assess the bias from population stratification in a particular study that did not account for race or ethnicity. We show here that, even in the most extreme situation, where a genotype is virtually universal in one group and absent in the other, the bias factor must lie between the ratio of disease rates in the two groups and its reciprocal. To see this, one must remember that the confounding risk ratio, CRR, which is a measure of the bias, depends on the ratio of the disease rates among those with the at-risk genotype and its frequency in the two groups, P1b and P1w (1) . When the rates or genotype frequencies are equal (RR ‫ס‬ 1 or P1b ‫ס‬ P1w), CRR is 1. If RR is greater than 1, then the confounding is positive, and CRR is greater than 1 when P1b is greater than P1w (2); CRR is below 1 (negative confounding) results when P1b is less than P1w. When P1b ‫ס‬ 1 and P1w ‫ס‬ 0, CRR equals RR; when P1b ‫ס‬ 0 and P1w ‫ס‬ 1, CRR equals 1/RR. Thus, the bias factor CRR must lie between the rate ratio RR and its reciprocal 1/RR, regardless of the differences in frequency of the atrisk genotype. Table 1 shows the CRR for various genotype frequencies when there are two groups split 20%-80%.
Millikan's results on the effects of controlling for race in a study of breast cancer in blacks and whites in North Carolina provide a good example of how one can predict the direction and extent of bias. Millikan reports that, in the North Carolina Breast Cancer Study, the empiric CRRs for adjusting by race lie between 0.94 and 1.12 when assessing the effects of several genotypes as risk factors for female breast cancer. Given that the ratio of breast cancer rates in blacks and in whites is 0.89, as reported by the North Carolina Central Cancer Registry for the period 1993 through 1997, the small estimated CRRs are consistent in magnitude with Table 1 and in the direction predicted by P1b/ P1w. Even for the most extreme differences in genotype frequencies, the bias factor from ignoring race will be bounded approximately by 0.89 and 1.12, if the black to white breast cancer incidence rate ratio from the Registry applies to the 20 study counties in North Carolina from 1993 through 1996. The column in Table 1 for RR ‫ס‬ 1.1 can be used as a more precise indicator of the bias for specified race-specific genotype frequencies.
In addition to a wide range of cancer rates and genotype frequencies among the groups, there are two requirements for important bias from population stratification when race or ethnicity is ignored (1). The genotype frequencies and cancer rates must vary together; clearly, with only two groups, they do so here. The differences in rates must remain after adjustment for known risk factors; while the North Carolina study collected information on all known breast cancer risk factors (3), it is unclear how much, if any, of the rate difference they explain.
In contrast to breast cancer, the ratio of incidence rates of prostate cancer in black and white males from 1993 through 1997 is near 1.7 in the Surveillance, Epidemiology, and End Results where P1b and P1w are the frequencies of the at-risk genotype in blacks and whites and P0b ‫ס‬ 1 − P1b and P0w ‫ס‬ 1 − P1w are their complements; Pb and Pw ‫ס‬ 1 − Pb are the proportions of blacks and whites in the study population; R0b and R0w are the disease rates in those without the genotype of interest, and RR ‫ס‬ R0b/R0w is the rte ratio. That is, the CRR is a ratio of the weighted averages of R0b and R0w; in the numerator, the weights are proportional to the fractions of blacks and whites with the at-risk genotype in the study population, while in the denominator the weights are proportional to the fractions of blacks and whites without the at-risk genotype. †Ratio of disease rates in group 1 to group 2 among those without the at-risk genotype.
Program. 1 In Table 1 , the column for RR ‫ס‬ 1.7 shows that failure to adjust for race in a study of genotypes with an extreme difference in frequency and prostate cancer is likely to have a greater impact than for breast cancer.
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NOTES
1 SEER is a set of geographically defined, population-based, central cancer registries in the United States, operated by local nonprofit organizations under contract to the National Cancer Institute (NCI). Registry data are submitted electronically without personal identifiers to the NCI on a biannual basis, and the NCI makes the data available to the public for scientific research.
